Information de reference pour ce titreAccession Number: | 00006676-201602000-00008.
|
Author: | Imaoka, Hiroshi MD *; Mizuno, Nobumasa MD *; Hara, Kazuo MD *; Hijioka, Susumu MD *; Tajika, Masahiro MD *; Tanaka, Tsutomu MD *; Ishihara, Makoto MD *; Yogi, Tatsuji MD *; Tsutsumi, Hideharu MD *; Fujiyoshi, Toshihisa MD *; Sato, Takamitsu MD *; Shimizu, Yasuhiro MD +; Niwa, Yasumasa MD *; Yamao, Kenji MD *
|
Institution: | From the Departments of *Gastroenterology and +Gastroenterological Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
|
Title: | |
Source: | Pancreas. 45(2):211-217, February 2016.
|
Abstract: | Objectives: The modified Glasgow prognostic score (mGPS) is known to be useful in determining the prognosis of cancers. However, the utility of mGPS for pancreatic cancer (PC) has been examined based primarily on a surgical series of early-stage cancers. The purpose of this study was to examine the utility of mGPS for PC of all stages using a retrospective cohort design.
Methods: We conducted a retrospective cohort study using data from a computerized database. A total of 807 patients with pathologically confirmed PC were analyzed (mGPS-0, n = 620; mGPS-1, n = 153; mGPS-2, n = 34).
Results: Median overall survival (OS) was significantly worse for the mGPS-1 group than for the mGPS-0 group (5.8 vs 15.8 months, respectively) but was comparable between the mGPS-2 and mGPS-1 groups (4.8 vs 5.8 months, respectively). After adjustment, both mGPS-1 and mGPS-2 were independent predictive factors of OS (mGPS-1: hazard ratio, 1.772; 95% confidence interval, 1.417-2.215; mGPS-2: hazard ratio, 2.033; 95% confidence interval, 1.284-3.219). Subgroup analysis showed that OS was significantly worse in the mGPS-1 and mGPS-2 groups than in the mGPS-0 group for all except the following 2 subgroups: localized disease and curative resection.
Conclusions: The present results show that the mGPS is an independent prognostic factor in patients with PC, especially for advanced-stage disease.
Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
|
Author Keywords: | albumin; C-reactive protein; modified Glasgow prognostic score; pancreatic cancer; prognostic factor.
|
References: | 1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29.
2. Gong Z, Holly EA, Bracci PM. Survival in population-based pancreatic cancer patients: San Francisco Bay area, 1995-1999. Am J Epidemiol. 2011; 174: 1373-1381.
3. Luo J, Xiao L, Wu C, et al. The incidence and survival rate of population-based pancreatic cancer patients: Shanghai Cancer Registry 2004-2009. PLoS One. 2013; 8: e76052.
4. Garcea G, Ladwa N, Neal CP, et al. Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma. World J Surg. 2011; 35: 868-872.
5. Jamieson NB, Denley SM, Logue J, et al. A prospective comparison of the prognostic value of tumor- and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2011; 18: 2318-2328.
6. Smith RA, Bosonnet L, Raraty M, et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 2009; 197: 466-472.
7. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25: 1960-1966.
8. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364: 1817-1825.
9. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369: 1691-1703.
10. McMillan DC, Crozier JE, Canna K, et al. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis. 2007; 22: 881-886.
11. Ishizuka M, Nagata H, Takagi K, et al. Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer. Ann Surg. 2009; 250: 268-272.
12. Kishiki T, Masaki T, Matsuoka H, et al. Modified Glasgow prognostic score in patients with incurable stage IV colorectal cancer. Am J Surg. 2013; 206: 234-240.
13. Leitch EF, Chakrabarti M, Crozier JE, et al. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer. 2007; 97: 1266-1270.
14. Hirashima K, Watanabe M, Shigaki H, et al. Prognostic significance of the modified Glasgow prognostic score in elderly patients with gastric cancer. J Gastroenterol. 2014; 49: 1040-1046.
15. Jiang X, Hiki N, Nunobe S, et al. Prognostic importance of the inflammation-based Glasgow prognostic score in patients with gastric cancer. Br J Cancer. 2012; 107: 275-279.
16. Nozoe T, Iguchi T, Egashira A, et al. Significance of modified Glasgow prognostic score as a useful indicator for prognosis of patients with gastric carcinoma. Am J Surg. 2011; 201: 186-191.
17. Jeong JH, Lim SM, Yun JY, et al. Comparison of two inflammation-based prognostic scores in patients with unresectable advanced gastric cancer. Oncology. 2012; 83: 292-299.
18. Barthel F, Royston P. Graphical representation of interactions. Stata J. 2006; 6: 348-363.
19. Raut CP, Tseng JF, Sun CC, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg. 2007; 246: 52-60.
20. Riediger H, Keck T, Wellner U, et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg. 2009; 13: 1337-1344.
21. Slidell MB, Chang DC, Cameron JL, et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol. 2008; 15: 165-174.
22. Luttges J, Schemm S, Vogel I, et al. The grade of pancreatic ductal carcinoma is an independent prognostic factor and is superior to the immunohistochemical assessment of proliferation. J Pathol. 2000; 191: 154-161.
23. Imaoka H, Shimizu Y, Mizuno N, et al. Clinical characteristics of adenosquamous carcinoma of the pancreas: a matched case-control study. Pancreas. 2014; 43: 287-290.
24. Kasymjanova G, MacDonald N, Agulnik JS, et al. The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer. Curr Oncol. 2010; 17: 52-58.
25. La Torre M, Nigri G, Cavallini M, et al. The Glasgow prognostic score as a predictor of survival in patients with potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2012; 19: 2917-2923.
26. Wang DS, Luo HY, Qiu MZ, et al. Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Med Oncol. 2012; 29: 3092-3100.
27. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15: 2403-2413.
28. Ueno H, Ioka T, Ikeda M, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013; 31: 1640-1648.
|
Language: | English.
|
Document Type: | Original Articles.
|
Journal Subset: | Clinical Medicine. Life & Biomedical Sciences.
|
ISSN: | 0885-3177
|
NLM Journal Code: | prs, 8608542
|
DOI Number: | https://dx.doi.org/10.1097/MPA.0...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|